MCID: BRN120
MIFTS: 44

Bronchus Cancer malady

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Bronchus Cancer

Aliases & Descriptions for Bronchus Cancer:

Name: Bronchus Cancer 12 14
Bronchial Neoplasms 42 69
Bronchus Carcinoma 12 14
Bronchial Neoplasm 12 14
Malignant Neoplasm of Bronchus and Lung, Unspecified 12
Malignant Neoplasm of Bronchus or Lung, Unspecified 12
Malignant Neoplasm of Bronchus or Lung Nos 12
Bc - Bronchogenic Carcinoma 12
Carcinoma, Bronchogenic 42
Bronchogenic Carcinoma 69
Neoplasm of Bronchus 12
Bronchus Neoplasm 12

Classifications:



Summaries for Bronchus Cancer

Disease Ontology : 12 A bronchus cancer that has material basis in epithelial cells.

MalaCards based summary : Bronchus Cancer, also known as bronchial neoplasms, is related to main bronchus cancer and bronchus carcinoma in situ, and has symptoms including coughing, dyspnea and fever. An important gene associated with Bronchus Cancer is CD6 (CD6 Molecule), and among its related pathways/superpathways are Vesicle-mediated transport and Vasopressin-regulated water reabsorption. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include lung, and related phenotypes are Decreased viability and homeostasis/metabolism

Related Diseases for Bronchus Cancer

Diseases in the Bronchus Cancer family:

Bronchus Carcinoma in Situ

Diseases related to Bronchus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
id Related Disease Score Top Affiliating Genes
1 main bronchus cancer 12.1
2 bronchus carcinoma in situ 11.9
3 lung cancer 10.9
4 bronchus mucoepidermoid carcinoma 10.9
5 pulmonary blastoma 10.1
6 pleuropulmonary blastoma type 1 10.1
7 pleuropulmonary blastoma type 2 10.1
8 pleuropulmonary blastoma type 3 10.1
9 immunodeficiency 9 10.1 CRP SAA1
10 anaplastic ganglioglioma 10.1 CRP SAA1
11 pyloric stenosis, infantile hypertrophic, 2 10.1 CRP SAA1
12 van maldergem syndrome 2 10.0 APP SAA1
13 omphalocele 10.0 AVP CRP
14 intestinal disaccharidase deficiency 10.0 AVP CRP
15 retinal arterial macroaneurysm with supravalvular pulmonic stenosis 10.0 AVP CRP
16 epidermolysis bullosa acquisita 10.0 AVPR2 CD6
17 hypertrophic elongation of cervix 10.0 AVP CRP
18 hard palate cancer 10.0 APP SAA1
19 chromosome xq28 duplication syndrome 9.9 AVP AVPR2
20 glossopharyngeal nerve neoplasm 9.9 AVP AVPR2
21 chondroma 9.9 AVP CRP
22 prediabetes syndrome 9.9 AVP AVPR2
23 kindler syndrome 9.9 AVP AVPR2
24 syringomelia hyperkeratosis 9.9 AVP AVPR2
25 calcinosis 9.9 AVP CRP
26 basal cell carcinoma 4 9.8 AVP AVPR2
27 cervix small cell carcinoma 9.8 APP CRP
28 fatty liver disease 9.8 AVP AVPR2
29 bronchiectasis 9.8
30 actinomycosis 9.7
31 situs inversus 9.6
32 superior vena cava syndrome 9.6
33 mediastinitis 9.6
34 esophagitis 9.6
35 cushing's syndrome 9.6
36 mucoepidermoid carcinoma 9.6
37 achalasia 9.6
38 adenoiditis 9.6
39 diverticulitis of colon 9.2 APP AVP AVPR2 CD6 CRP SAA1

Graphical network of the top 20 diseases related to Bronchus Cancer:



Diseases related to Bronchus Cancer

Symptoms & Phenotypes for Bronchus Cancer

UMLS symptoms related to Bronchus Cancer:


coughing, dyspnea, fever, hemoptysis

GenomeRNAi Phenotypes related to Bronchus Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 8.92 AVPR2 SAA1
2 Decreased viability GR00381-A-3 8.92 AVPR2 SAA1

MGI Mouse Phenotypes related to Bronchus Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.1 APP AVP AVPR2 CD6 CRP SAA1

Drugs & Therapeutics for Bronchus Cancer

Drugs for Bronchus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 720)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 150399-23-8, 137281-23-3 446556 60843
4
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
5
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1 33419-42-0 36462
6
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
7
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
8
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
9
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
10
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
11
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
12
Trioxsalen Approved Phase 4,Phase 2 3902-71-4 5585
13
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
14
Crizotinib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
15
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
16
Armodafinil Approved, Investigational Phase 4,Phase 1,Phase 2 112111-43-0
17
Modafinil Approved, Investigational Phase 4,Phase 1,Phase 2 68693-11-8 4236
18
Zoledronic acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
19
Nitric Oxide Approved Phase 4 10102-43-9 145068
20
Budesonide Approved Phase 4,Phase 2,Phase 3,Phase 1 51333-22-3 63006 5281004
21
Theophylline Approved Phase 4,Phase 1 58-55-9 2153
22
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1 2216-51-5 16666
23
Osimertinib Approved Phase 4,Phase 2,Phase 3,Phase 1 1421373-65-0 71496458
24
Pembrolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 1374853-91-4
25
Montelukast Approved Phase 4,Phase 2 158966-92-8 5281040
26
Desflurane Approved Phase 4 57041-67-5 42113
27
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
28
Remifentanil Approved Phase 4 132875-61-7 60815
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
30
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
31
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
32
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 114977-28-5 148124 9877265
33
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
34 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
35 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Endostatins Phase 4,Phase 3,Phase 2,Phase 1 71581480
38 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
40 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
41 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1
47 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
48 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1
49 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
50
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 183319-69-9 176871

Interventional clinical trials:

(show top 50) (show all 3911)
id Name Status NCT ID Phase
1 Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Unknown status NCT00813332 Phase 4
2 Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4
3 PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC) Unknown status NCT00173524 Phase 4
4 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4
5 Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01211002 Phase 4
6 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4
7 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4
8 Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population Completed NCT02000531 Phase 4
9 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4
10 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4
11 Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose Completed NCT01465243 Phase 4
12 Iressa Case Control Study in Japan Completed NCT00252759 Phase 4
13 Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC Completed NCT02497118 Phase 4
14 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4
15 An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00949910 Phase 4
16 A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) Completed NCT00388206 Phase 4
17 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4
18 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed NCT00770588 Phase 4
19 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4
20 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4
21 A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01196078 Phase 4
22 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4
23 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients Completed NCT01020786 Phase 4
24 Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) Completed NCT00686322 Phase 4
25 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed NCT01287754 Phase 4
26 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Completed NCT00451906 Phase 4
27 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Completed NCT01230710 Phase 4
28 Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab Completed NCT02316327 Phase 4
29 Pemetrexed Followed by Docetaxel or in Reverse Sequence Completed NCT01442909 Phase 4
30 A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
31 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4
32 Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy Completed NCT00115206 Phase 4
33 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Completed NCT02972216 Phase 4
34 SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients Completed NCT00608868 Phase 4
35 Effect of Prolonged Decubitus on Nitric Oxide Concentration in Chronic Obstructive Pulmonary Disease Completed NCT01555593 Phase 4
36 Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study Completed NCT01853787 Phase 4
37 Ultrathin Bronchoscopy for Solitary Pulmonary Nodules Completed NCT02490059 Phase 4
38 The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis Completed NCT01769898 Phase 4
39 The Effect of Theophylline in the Treatment of Bronchiectasis Completed NCT01684683 Phase 4
40 Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC Recruiting NCT01848613 Phase 4
41 Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Recruiting NCT01665417 Phase 4
42 Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer Recruiting NCT02916745 Phase 4
43 Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Recruiting NCT02514174 Phase 4
44 Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Recruiting NCT01926171 Phase 4
45 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Recruiting NCT02103257 Phase 4
46 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Recruiting NCT02513355 Phase 4
47 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Recruiting NCT02348450 Phase 4
48 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Recruiting NCT02031601 Phase 4
49 Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation Recruiting NCT02962999 Phase 4
50 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation Active, not recruiting NCT02208843 Phase 4

Search NIH Clinical Center for Bronchus Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: bronchial neoplasms

Genetic Tests for Bronchus Cancer

Anatomical Context for Bronchus Cancer

MalaCards organs/tissues related to Bronchus Cancer:

39
Lung

Publications for Bronchus Cancer

Articles related to Bronchus Cancer:

(show all 11)
id Title Authors Year
1
Racial and Gender Disparities in Incidence of Lung and Bronchus Cancer in the United States: A Longitudinal Analysis. ( 27685944 )
2016
2
Dosimetric impact of an air passage on intraluminal brachytherapy for bronchus cancer. ( 27605630 )
2016
3
Incidence rates for lung and bronchus cancer of Japanese in Japan and in the United States from the Cancer Incidence in Five Continents. ( 27380807 )
2016
4
Stat Bite Percentage of New Caces by Age Group For Lung and Bronchus Cancer (2008-2012). ( 26944763 )
2016
5
Lung and bronchus cancer in Puerto Rico: changes in incidence and mortality rates by histology and sex during 1987-2003: comment on the article by Rivas et al. ( 22783701 )
2012
6
Lung and bronchus cancer in Puerto Rico: changes in incidence and mortality rates by histology and sex during 1987-2003. ( 22263297 )
2011
7
Superior vena cava syndrome in a man with situs inversus totalis and left main bronchus cancer. ( 19507488 )
2009
8
Lung and bronchus cancer disparities in South Carolina: epidemiology and strategies for prevention. ( 17319229 )
2006
9
Stat bite: Mortality from lung and bronchus cancer by race/ethnicity, 1998-2002. ( 16449672 )
2006
10
Stat bite: Incidence of lung and bronchus cancer by ethnicity, 1996-2000. ( 12902435 )
2003
11
Lung and bronchus cancer in women: a 21st-century epidemic. ( 12370622 )
2002

Variations for Bronchus Cancer

Cosmic variations for Bronchus Cancer:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10656 TP53 lung,bronchus,carcinoma,NS c.742C>T p.R248W 16
2 COSM10660 TP53 lung,bronchus,carcinoma,NS c.818G>A p.R273H 16
3 COSM10718 TP53 lung,bronchus,carcinoma,NS c.524G>T p.R175L 16
4 COSM10662 TP53 lung,bronchus,carcinoma,NS c.743G>A p.R248Q 16
5 COSM10779 TP53 lung,bronchus,carcinoma,NS c.818G>T p.R273L 16
6 COSM6213 EGFR lung,bronchus,carcinoma,NS c.2582T>A p.L861Q 16

Expression for Bronchus Cancer

Search GEO for disease gene expression data for Bronchus Cancer.

Pathways for Bronchus Cancer

Pathways related to Bronchus Cancer according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 APP AVP AVPR2 SAA1
2 10.6 AVP AVPR2
3 9.74 APP SAA1

GO Terms for Bronchus Cancer

Cellular components related to Bronchus Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.46 APP AVP CRP SAA1
2 extracellular region GO:0005576 9.02 APP AVP CD6 CRP SAA1
3 clathrin-coated vesicle membrane GO:0030665 8.96 AVP AVPR2

Biological processes related to Bronchus Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.54 APP CD6 SAA1
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.43 AVP SAA1
3 locomotory behavior GO:0007626 9.4 APP AVP
4 acute-phase response GO:0006953 9.32 CRP SAA1
5 positive regulation of vasoconstriction GO:0045907 9.26 AVP AVPR2
6 renal water homeostasis GO:0003091 9.16 AVP AVPR2
7 positive regulation of systemic arterial blood pressure GO:0003084 8.96 AVP AVPR2
8 positive regulation of gene expression GO:0010628 8.92 APP AVP AVPR2 CRP

Sources for Bronchus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....